Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection.
AuthorsO'Seaghdha, C M
Moran, A M
Mohan, D M
Hickey, D P
Conlon, P J
AffiliationDepartment of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.
Drug Therapy, Combination
MetadataShow full item record
CitationHigher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection., 23 (4):462-8 Clin Transplant
AbstractWe analyzed the association between whole-blood trough tacrolimus (TAC) levels in the first days post-kidney transplant and acute cellular rejection (ACR) rates. Four hundred and sixty-four consecutive, deceased-donor kidney transplant recipients were included. All were treated with a combination of TAC, mycophenolate mofetil and prednisolone. Patients were analyzed in four groups based on quartiles of the mean TAC on days 2 and 5 post-transplant: Group 1: median TAC 11 ng/mL (n = 122, range 2-13.5 ng/mL), Group 2: median 17 ng/mL (n = 123, range 14-20 ng/mL), Group 3: median 24 ng/mL (n = 108, range 20.5-27 ng/mL) and Group 4: median 33.5 ng/mL (n = 116, range 27.5-77.5 ng/mL). A graded reduction in the rates of ACR was observed for each incremental days 2-5 TAC. The one-yr ACR rate was 24.03% (95% CI 17.26-32.88), 22.20% (95% CI 15.78-30.70), 13.41% (95% CI 8.15-21.63) and 8.69% (95% CI 4.77-15.55) for Groups 1-4, respectively (p = 0.003). This study suggests that higher early TACs are associated with reduced rates of ACR at one yr.
- A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
- Authors: Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J
- Issue date: 2004 Jan 27
- Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
- Authors: Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB
- Issue date: 2007 May 27
- Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
- Authors: Demirbaş A, Tuncer M, Yavuz A, Gürkan A, Kaçar S, Cetinkaya R, Tekin S, Akbaş SH, Akaydin M, Ersoy F, Yakupoğlu G
- Issue date: 2004 Jan-Feb
- Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
- Authors: Gralla J, Wiseman AC
- Issue date: 2009 Jun 15
- One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
- Authors: Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G
- Issue date: 2005 Jan